Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTIESG)

• Drug Name: Omburtamab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Neuroblastoma	2D11.2	Phase 2/3	[1]

• Cross-matching ID: TTD Drug ID: DMTIESG

Molecule-Related Drug Atlas

Drug(s) Targeting B7 homolog 3 (CD276)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omburtamab I-131	DMPDA17	Neuroblastoma	2D11.2	Phase 2/3	[3]
131 I-omburtamab	DM12UX6	Brain and central nervous system tumour	2A00.11	Phase 2/3	[4]
Enoblituzumab	DMDS20X	Prostate cancer	2C82.0	Phase 2	[5]
TAK-280	DM08RE5	Aggressive cancer	2A00-2F9Z	Phase 2	[6]
DS-7300	DMK4VY9	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
Omburtamab I-124	DMPLBDF	Glioma	2A00.0	Phase 1/2	[3]
MGC018	DM1KZW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
MGD009	DME4B8I	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
MGA271	DM2PVLH	Metastatic cancer	2D50-2E2Z	Phase 1	[9]
124I-8H9	DM5ZC0E	Glioblastoma multiforme	2A00.0	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B7 homolog 3 (CD276)	TT6CQUM	CD276_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03275402) 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases. U.S. National Institutes of Health.
• [2] Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [8] Clinical pipeline report, company report or official report of MacroGenics.
• [9] T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236.
• [10] National Cancer Institute Drug Dictionary (drug id 722029).